Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
IPHA Quote, Financials, Valuation and Earnings
Last price:
$1.61
Seasonality move
:
-6.73%
Day range:
$1.62 - $1.71
52-week range:
$1.57 - $2.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.31x
P/B ratio:
20.75x
Volume:
4.3K
Avg. volume:
20.3K
1-year change:
-22.17%
Market cap:
$154.6M
Revenue:
$13.7M
EPS (TTM):
-$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
$2.6M | -- | -- | -- | $5.00 |
|
CLLS
Cellectis SA
|
$12.7M | -$0.11 | 24.25% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.22 | -- | -86.12% | $40.07 |
|
GNFTF
Genfit SA
|
$33.6M | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -- | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
$1.65 | $5.00 | $154.6M | -- | $0.00 | 0% | 21.31x |
|
CLLS
Cellectis SA
|
$3.80 | $7.25 | $382.2M | -- | $0.00 | 0% | 4.73x |
|
DBVT
DBV Technologies SA
|
$23.25 | $40.07 | $1.3B | -- | $0.00 | 0% | -- |
|
GNFTF
Genfit SA
|
$10.50 | -- | $525.4M | 49.25x | $0.00 | 0% | 11.55x |
|
NICXF
Nicox SA
|
$0.30 | -- | $24.3M | -- | $0.00 | 0% | 5.89x |
|
TRGNF
Transgene SA
|
$1.00 | -- | $132.3M | -- | $0.00 | 0% | 1,122.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
55.22% | 0.092 | -- | 2.76x |
|
CLLS
Cellectis SA
|
54.27% | -0.262 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.983 | 5.85% | 1.41x |
|
GNFTF
Genfit SA
|
-- | -1.901 | -- | -- |
|
NICXF
Nicox SA
|
54.24% | 0.872 | 91.41% | 1.21x |
|
TRGNF
Transgene SA
|
-- | 0.550 | -- | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
GNFTF
Genfit SA
|
-- | -- | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -24.01% | -43.13% | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -182.92% | -182.92% | -- | -- |
Innate Pharma SA vs. Competitors
-
Which has Higher Returns IPHA or CLLS?
Cellectis SA has a net margin of -- compared to Innate Pharma SA's net margin of 1.68%. Innate Pharma SA's return on equity of -72.79% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About IPHA or CLLS?
Innate Pharma SA has a consensus price target of $5.00, signalling upside risk potential of 203.03%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 90.79%. Given that Innate Pharma SA has higher upside potential than Cellectis SA, analysts believe Innate Pharma SA is more attractive than Cellectis SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 CLLSCellectis SA2 2 0 -
Is IPHA or CLLS More Risky?
Innate Pharma SA has a beta of -0.023, which suggesting that the stock is 102.261% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.855, suggesting its more volatile than the S&P 500 by 185.46%.
-
Which is a Better Dividend Stock IPHA or CLLS?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or CLLS?
Innate Pharma SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. Innate Pharma SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 21.31x versus 4.73x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA21.31x -- -- -- CLLSCellectis SA4.73x -- $35M $586.4K
-
Which has Higher Returns IPHA or DBVT?
DBV Technologies SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About IPHA or DBVT?
Innate Pharma SA has a consensus price target of $5.00, signalling upside risk potential of 203.03%. On the other hand DBV Technologies SA has an analysts' consensus of $40.07 which suggests that it could grow by 72.34%. Given that Innate Pharma SA has higher upside potential than DBV Technologies SA, analysts believe Innate Pharma SA is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 DBVTDBV Technologies SA4 0 1 -
Is IPHA or DBVT More Risky?
Innate Pharma SA has a beta of -0.023, which suggesting that the stock is 102.261% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.975, suggesting its less volatile than the S&P 500 by 197.455%.
-
Which is a Better Dividend Stock IPHA or DBVT?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or DBVT?
Innate Pharma SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 21.31x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA21.31x -- -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns IPHA or GNFTF?
Genfit SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Genfit SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M GNFTFGenfit SA-- -- -- -
What do Analysts Say About IPHA or GNFTF?
Innate Pharma SA has a consensus price target of $5.00, signalling upside risk potential of 203.03%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Innate Pharma SA has higher upside potential than Genfit SA, analysts believe Innate Pharma SA is more attractive than Genfit SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 GNFTFGenfit SA0 0 0 -
Is IPHA or GNFTF More Risky?
Innate Pharma SA has a beta of -0.023, which suggesting that the stock is 102.261% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 99.966%.
-
Which is a Better Dividend Stock IPHA or GNFTF?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or GNFTF?
Innate Pharma SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Genfit SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 49.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 21.31x versus 11.55x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA21.31x -- -- -- GNFTFGenfit SA11.55x 49.25x -- --
-
Which has Higher Returns IPHA or NICXF?
Nicox SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Nicox SA's return on equity of -43.13%.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M NICXFNicox SA-- -- $46.8M -
What do Analysts Say About IPHA or NICXF?
Innate Pharma SA has a consensus price target of $5.00, signalling upside risk potential of 203.03%. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Innate Pharma SA has higher upside potential than Nicox SA, analysts believe Innate Pharma SA is more attractive than Nicox SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 NICXFNicox SA0 0 0 -
Is IPHA or NICXF More Risky?
Innate Pharma SA has a beta of -0.023, which suggesting that the stock is 102.261% less volatile than S&P 500. In comparison Nicox SA has a beta of -0.051, suggesting its less volatile than the S&P 500 by 105.13%.
-
Which is a Better Dividend Stock IPHA or NICXF?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or NICXF?
Innate Pharma SA quarterly revenues are --, which are smaller than Nicox SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Nicox SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 21.31x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA21.31x -- -- -- NICXFNicox SA5.89x -- -- --
-
Which has Higher Returns IPHA or TRGNF?
Transgene SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Transgene SA's return on equity of -182.92%.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M TRGNFTransgene SA-- -- -$660.3K -
What do Analysts Say About IPHA or TRGNF?
Innate Pharma SA has a consensus price target of $5.00, signalling upside risk potential of 203.03%. On the other hand Transgene SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Innate Pharma SA has higher upside potential than Transgene SA, analysts believe Innate Pharma SA is more attractive than Transgene SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 TRGNFTransgene SA0 0 0 -
Is IPHA or TRGNF More Risky?
Innate Pharma SA has a beta of -0.023, which suggesting that the stock is 102.261% less volatile than S&P 500. In comparison Transgene SA has a beta of 43.826, suggesting its more volatile than the S&P 500 by 4282.564%.
-
Which is a Better Dividend Stock IPHA or TRGNF?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Transgene SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Transgene SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or TRGNF?
Innate Pharma SA quarterly revenues are --, which are smaller than Transgene SA quarterly revenues of $105.2K. Innate Pharma SA's net income of -- is lower than Transgene SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Transgene SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 21.31x versus 1,122.44x for Transgene SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA21.31x -- -- -- TRGNFTransgene SA1,122.44x -- $105.2K --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 14.27% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 7.5% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.39% over the past day.
